You are here

Study Of "Continuous Use" Of Celecoxib Vs. "Usual or Intermittent Use"

Last updated on February 22, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Huntsville, Alabama, 35801 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Knee Osteoarthritis, Hip Osteoarthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-80 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subject has been diagnosed, according to American College of Rheumatology guidelines,
with osteoarthritis of the hip or knee and requires non-steroidal anti-inflammatory
drugs (NSAIDs) to control their osteoarthritis pain and have access to a touch-tone
telephone.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Subject has had surgery on index joint.

- Subject has history of rheumatoid arthritis or fibromyalgia syndrome.

- Subject has active gastrointestinal or cardiovascular disease.

NCT00139776
Pfizer
Completed
Study Of "Continuous Use" Of Celecoxib Vs. "Usual or Intermittent Use"

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Knee Osteoarthritis, Hip Osteoarthritis
NCT00139776
All Genders
18+
Years
Multiple Sites
Chronic Pain, Hip Osteoarthritis, Knee Osteoarthritis
NCT02528188
All Genders
18+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now